Loading news...
Alpha Teknova (NASDAQ: TKNO) executives told investors the company delivered faster growth and improved profitability metrics in 2025, and said they believe the business is approaching an "inflection point" as it scales its mix of research-grade and GMP-grade reagents. On the company's fourth-quarter and full-year 2025 earnings call, management highlighted rising clinical customer counts, improving manufacturing
Alpha Teknova, Inc. (TKNO) Q4 2025 Earnings Call Transcript
Full year 2025 total revenue was $40.5 million, up 7% year-over-year and in line with guidance Fourth quarter 2025 total revenue was $10.0 million, up 8% over the same quarter prior year Company provides 2026 revenue guidance of $42-44 million
HOLLISTER, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026, following the close of market.
Alpha Teknova, Inc. (NASDAQ: TKNO - Get Free Report)'s stock price traded up 2.6% during mid-day trading on Friday. The company traded as high as $3.94 and last traded at $3.90. 142,045 shares were traded during mid-day trading, a decline of 10% from the average session volume of 158,186 shares. The stock had previously closed
Shares of Alpha Teknova, Inc. (NASDAQ: TKNO - Get Free Report) traded down 1.3% on Friday. The stock traded as low as $4.61 and last traded at $4.69. 71,686 shares changed hands during trading, a decline of 64% from the average session volume of 197,372 shares. The stock had previously closed at $4.75. Wall Street
Alpha Teknova, Inc. ( TKNO ) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President, CEO & Director Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Etoch - Stephens Inc., Research Division Brendan Smith - TD Cowen, Research Division Matthew Larew - William Blair & Company L.L.C., Research Division Tollef Kohrman - Craig-Hallum Capital Group LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Presentation Operator Good day, and thank you for standing by.
Third quarter 2025 total revenue was $10.5 million, up 9% from prior year Achieves five consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million
HOLLISTER, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the third quarter ended September 30, 2025, on Thursday, November 6, 2025, following the close of market.
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q2 2025 Earnings Conference Call August 7, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Matthew C. Lowell - Chief Financial Officer Stephen Gunstream - President, CEO & Director Conference Call Participants Brendan Mychal Smith - TD Cowen, Research Division Matthew Moriarty Parisi - KeyBanc Capital Markets Inc., Research Division Matthew Richard Larew - William Blair & Company L.L.C.
Second quarter 2025 total revenue was $10.3 million, up 7% from prior year Achieves four consecutive quarters of year-over-year revenue growth Company reaffirms 2025 revenue guidance of $39-42 million HOLLISTER, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financial results for the second quarter ended June 30, 2025.
HOLLISTER, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, following the close of market.
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q1 2025 Results Conference Call May 8, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Anna Snopkowski - KeyBanc Matt Hewitt - Craig-Hallum Capital Group Matt Larew - William Blair Chad Wiatrowski - TD Cowen Operator Good day, and thank you for standing by. Welcome to the Teknova First Quarter 2025 Financial Results Conference Call.
First quarter 2025 total revenue was $9.8 million, up 5% from prior year Company introduced proprietary PluriFreeze™ cryopreservation system, in collaboration with Pluristyx, Inc. Company reaffirms 2025 revenue guidance of $39-42 million
HOLLISTER, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the first quarter ended March 31, 2025, on Thursday, May 8, 2025, following the close of market.
HOLLISTER, Calif., March 19, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), and Pluristyx, Inc., today announced that Pluristyx's PluriFreeze™ cryopreservation system is available for purchase exclusively from Teknova.
Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System Teknova to Become the Exclusive Manufacturer and Distributor of Pluristyx's Novel PluriFreeze™ Cryopreservation System
Alpha Teknova, Inc. (NASDAQ:TKNO ) Q4 2024 Earnings Call March 4, 2025 5:00 PM ET Company Participants Jennifer Henry - Senior Vice President, Marketing Stephen Gunstream - President and Chief Executive Officer Matt Lowell - Chief Financial Officer Conference Call Participants Matt Larew - William Blair Matthew Parisi - KeyBanc Capital Markets Mark Massaro - BTIG Matt Hewitt - Craig-Hallum Operator Thank you for standing by, and welcome to Teknova's Fourth Quarter and Full Year 2024 Earnings Conference Call. [Operator Instructions] I would now like to hand the call over to Jennifer Henry, Senior Vice President of Marketing.
Full year 2024 total revenue was $37.7 million, up 3% year-over-year and in line with guidance Fourth quarter 2024 total revenue was $9.3 million, up 18% over the same quarter prior year Company provides 2025 revenue guidance of $39-42 million
HOLLISTER, Calif., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2024, on Tuesday, March 4, 2025, following the close of market.